CRDF

Cardiff Oncology, Inc. (CRDF) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel therapies based on Polo-like Kinase 1 (PLK1) inhibition. The company's lead asset is onvansertib, an oral PLK1 inhibitor currently in clinical trials for RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and metastatic triple-negative breast cancer (mTNBC).

Key Financial Metrics

Note: Revenue consists entirely of royalty revenues from legacy intellectual property licenses unrelated to onvansertib.

Material Changes vs. Prior Period

• Revenue Decline: Royalty revenues decreased 26% year-over-year for the quarter and 38% year-over-year for the six-month period, driven by the timing of licensee sales activities.
• Increased Operating Expenses: Total operating expenses rose 17% in Q2 and 23% YTD compared to 2024.
  • R&D Expenses: Increased by $2.1 million (Q2) and $4.6 million (YTD), primarily due to costs associated with the CRDF-004 Phase 2 clinical trial and increased clinical trial services.
  • SG&A Expenses: Increased by $0.1 million (Q2) and $1.0 million (YTD), driven by higher stock-based compensation and professional fees for strategic advisory services.
• Cash Position: Cash and cash equivalents decreased from $51.5 million at year-end 2024 to $10.8 million at June 30, 2025. However, total liquidity (including short-term investments) remains at $71.0 million.
• Net Loss Improvement: Despite higher expenses, net loss per share improved from $(0.26) to $(0.21) in Q2 and from $(0.49) to $(0.41) YTD, largely due to a significant increase in the weighted-average shares outstanding (from ~44.8M to ~66.5M) following a prior equity issuance.

Outlook, Risks, and Management Commentary

• Liquidity: Management states it has sufficient cash to meet funding requirements for at least the next 12 months and projects capital resources to fund operations into the first quarter of 2027. The company expects to continue incurring losses and may require additional capital, which could result in shareholder dilution.
• Clinical Progress:
  • CRDF-004 (mCRC): Enrollment of ~90 patients completed in April 2025. Preliminary data showed an Objective Response Rate (ORR) of 57% for onvansertib + SoC vs. 33% for SoC alone. A Phase 3 trial (CRDF-005) is planned contingent on these results.
  • mTNBC: Positive data presented at ASCO in June 2025 showed a 40% ORR for onvansertib + paclitaxel.
  • mPDAC: An investigator-initiated trial with NALIRIFOX is open for enrollment.
• Corporate Updates: Roger Sidhu, M.D., was appointed Chief Medical Officer in June 2025. A new patent for onvansertib in mCRC treatment was issued in April 2025, with an expiration date no earlier than 2043.
• Risks: The company faces standard biotech risks including clinical trial failure, regulatory delays, and the need for future capital raises. There are no material pending legal proceedings.

Investor Verification Checklist

• Cash Runway: Verify the specific monthly burn rate to confirm the "first quarter of 2027" funding projection given the $40.7 million net decrease in cash over the last six months.
• CRDF-004 Data Readout: Monitor for the full data readout of the CRDF-004 Phase 2 trial to assess the likelihood of initiating the registrational Phase 3 trial.
• Equity Dilution: Review the 2021 Equity Incentive Plan and outstanding options (11.7M options, 2.8M warrants) to understand potential dilution if further capital is raised.
• Royalty Volatility: Acknowledge that current revenue is non-recurring and dependent on third-party sales, not product sales of onvansertib.